September 3, 2026 Ref: NEPHROPLUS/SE/83

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai - 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai - 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of Employee Stock Options under the NephroPlus Employee Stock Option Scheme 2026

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we hereby inform you that the Nomination and Remuneration Committee ("**NRC**") of the Board of Directors of Nephrocare Health Services Limited ("**Company**"), by way of resolution(s) passed by circulation on September 3, 2026, has approved the grant of an aggregate of 4,01,362 (Four Lakh One Thousand Three Hundred and Sixty-Two) Employee Stock Options ("**Options**") under the NephroPlus Employee Stock Option Scheme 2026 ("**ESOP 2026**" or "**Scheme**") to eligible employees identified by the NRC.

Each Option, upon vesting and exercise in accordance with the terms and conditions of ESOP 2026 and the respective Grant Letters, shall entitle the Option Grantee to acquire one fully paid-up equity share of the Company having a face value of ₹2/- (Rupees Two only) each. The Options have been granted at an exercise price of ₹230/- (Rupees Two Hundred and Thirty only) per Option and shall vest subject to fulfilment of the applicable vesting conditions, as specified in the respective Grant Letters.

The relevant details with respect to above item as required under SEBI Listing Regulations read with SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFDPOD2/ I/3762/2026 dated January 30, 2026 is enclosed as **Annexure I.**

The aforesaid information is also being made available on the website of the Company at www.nephroplus.com.

For **Nephrocare Health Services Limited**
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore
Digitally signed by Kathri Kishore
Date: 2026.09.03 11:02:15 +05'30'

Kishore Kathri
Company Secretary and Head Legal
Membership No.: F9895

Encl.: As above

Annexure I

Details of grant of Employee Stock Options under the NephroPlus Employee Stock Option Scheme 2026

Sr. No.	Particulars	Details
1	Brief details of Options granted	The NRC has approved the grant of an aggregate of 4,01,362 (Four Lakh One Thousand Three Hundred and Sixty-Two) Employee Stock Options ("**Options**") under ESOP 2026 to eligible employees of the Company. Each Option, upon vesting and exercise, shall entitle the Option Grantee to acquire one fully paid-up equity share of the Company having a face value of ₹2/- each.
2	Whether the Scheme is in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021	Yes. ESOP 2026 is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("**SEBI SBEB Regulations**").
3	Total number of shares covered by these Options	4,01,362 equity shares of face value of ₹2/- each may arise upon exercise of the Options, assuming vesting and exercise of all Options granted. Each Option is convertible into one equity share of the Company.
4	Pricing formula / Exercise Price	The Options have been granted at an Exercise Price of ₹230/- (Rupees Two Hundred and Thirty only) per Option, as determined by the NRC in accordance with ESOP 2026 and specified in the respective Grant Letters.
5	Options vested	Not applicable at this stage. The Options granted are subject to a minimum vesting period of one year from the Grant Date and fulfilment of the applicable Vesting Conditions and other terms specified in the respective Grant Letters.
6	Time within which Options may be exercised	The Vested Options may be exercised within a maximum period of 5 (five) years from the date of each respective Vesting, or within such shorter period as may be prescribed by the Nomination and Remuneration Committee and specified in the relevant Grant Letter, subject to the terms and conditions of ESOP 2026. In the event of cessation of employment/service or other specified events, the Exercise Period shall be governed by the applicable provisions of ESOP 2026.
7	Options exercised	Not applicable at this stage.
8	Money realised by exercise of Options	Not applicable at this stage.
9	Total number of shares arising as a result of exercise of Options	Not applicable at this stage.
10	Options lapsed	Not applicable at this stage.

11	Variation of terms of Options	Not applicable at this stage.
12	Brief details of significant terms	The Options shall be governed by ESOP 2026, the respective Grant Letters and the SEBI SBEB Regulations, and shall vest subject to the fulfilment of the applicable vesting conditions as approved by the Nomination and Remuneration Committee ("**NRC**") and set out in the respective Grant Letters, as accepted by the Option Grantees. The Options shall, in all circumstances, be subject to the applicable minimum vesting period prescribed under ESOP 2026 and applicable law. In the event the applicable vesting conditions are not fulfilled within the period stipulated in the respective Grant Letters, the corresponding unvested Options shall automatically lapse and be returned to the pool under ESOP 2026 for future grants, without requiring any further act, action or approval of the NRC.
13	Subsequent changes or cancellation or exercise of such Options	Not applicable at this stage.
14	Diluted earnings per share pursuant to issue of equity shares on exercise of Options	Not applicable at this stage.

***

Nephrocare Health Services Limited (Global Corporate Headquarters)
(Formerly Nephrocare Health Services Private Limited)
5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500 081, Telangana, India.
+91 40 4240 8039 contactus@nephroplus.com www.nephroplus.com
CIN: L85100TG2009PLC066359 | GSTIN: 36AADCN1504A1Z8 | ISD GST: 36AADCN1504A2Z7